William Duckworth

Summary

Country: USA

Publications

  1. ncbi Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies
    William Duckworth
    Carl T Hayden VA Medical Center, Arizona State University, Phoenix, AZ 85012, USA
    J Diabetes Complications 21:196-204. 2007
  2. ncbi Racial and ethnic disparities in the control of cardiovascular disease risk factors in Southwest American veterans with type 2 diabetes: the Diabetes Outcomes in Veterans Study
    Christopher S Wendel
    Southern Arizona VA Health Care System, Tucson, AZ 85723, USA
    BMC Health Serv Res 6:58. 2006
  3. ncbi The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial
    William C Duckworth
    Phoenix VA Health Care Center, Phoenix, AZ 85012, USA
    J Diabetes Complications 25:355-61. 2011
  4. ncbi Glucose control and vascular complications in veterans with type 2 diabetes
    William Duckworth
    Phoenix Veterans Affairs Health Care Center, Phoenix, AZ 85012, USA
    N Engl J Med 360:129-39. 2009
  5. ncbi Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis
    Peter D Reaven
    Phoenix Veterans Affairs Health Care System, Phoenix, Arizona, USA
    Diabetes 58:2642-8. 2009
  6. ncbi Proliferative diabetic retinopathy in type 2 diabetes is related to coronary artery calcium in the Veterans Affairs Diabetes Trial (VADT)
    Peter D Reaven
    Carl T Hayden VA Medical Center, Phoenix, Arizona 85012 1892, USA
    Diabetes Care 31:952-7. 2008
  7. ncbi Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea coadministered with metformin to glyburide-metformin tablets
    William Duckworth
    Carl T. Hayden VA Medical Center, Phoenix, AZ, USA
    J Manag Care Pharm 9:256-62. 2003
  8. ncbi Preliminary report: hepatic fat and inflammation in type 2 diabetes mellitus
    Aramesh Saremi
    Phoenix VA Health Care System, Phoenix, AZ 85012 1892, USA
    Metabolism 59:430-2. 2010
  9. ncbi Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D)
    Linda F Fried
    Veterans Affairs Pittsburgh Healthcare System and Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylviania 15240, USA
    Clin J Am Soc Nephrol 4:361-8. 2009
  10. ncbi Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial
    Robert J Anderson
    Section of Endocrinology, VA Medical Center, Omaha, Nebraska, USA
    Diabetes Care 34:34-8. 2011

Detail Information

Publications13

  1. ncbi Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies
    William Duckworth
    Carl T Hayden VA Medical Center, Arizona State University, Phoenix, AZ 85012, USA
    J Diabetes Complications 21:196-204. 2007
    ..The known pathophysiology of Type 2 diabetes and the need for basal insulin treatment are presented as rationale for comparison of these insulins...
  2. ncbi Racial and ethnic disparities in the control of cardiovascular disease risk factors in Southwest American veterans with type 2 diabetes: the Diabetes Outcomes in Veterans Study
    Christopher S Wendel
    Southern Arizona VA Health Care System, Tucson, AZ 85723, USA
    BMC Health Serv Res 6:58. 2006
    ..We examined the association between race/ethnicity and cardiovascular disease risk factor control in a large cohort of insulin-treated veterans with type 2 diabetes...
  3. ncbi The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial
    William C Duckworth
    Phoenix VA Health Care Center, Phoenix, AZ 85012, USA
    J Diabetes Complications 25:355-61. 2011
    ..No significant benefit was found. This report examines predictors of the effect of intensive therapy on the primary outcome in this population...
  4. ncbi Glucose control and vascular complications in veterans with type 2 diabetes
    William Duckworth
    Phoenix Veterans Affairs Health Care Center, Phoenix, AZ 85012, USA
    N Engl J Med 360:129-39. 2009
    ..The effects of intensive glucose control on cardiovascular events in patients with long-standing type 2 diabetes mellitus remain uncertain...
  5. ncbi Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis
    Peter D Reaven
    Phoenix Veterans Affairs Health Care System, Phoenix, Arizona, USA
    Diabetes 58:2642-8. 2009
    ..This study investigated the hypothesis that baseline calcified coronary atherosclerosis may determine cardiovascular disease events in response to intensive glycemic control within the Veterans Affairs Diabetes Trial (VADT)...
  6. ncbi Proliferative diabetic retinopathy in type 2 diabetes is related to coronary artery calcium in the Veterans Affairs Diabetes Trial (VADT)
    Peter D Reaven
    Carl T Hayden VA Medical Center, Phoenix, Arizona 85012 1892, USA
    Diabetes Care 31:952-7. 2008
    ..We determined the relationship between retinopathy and coronary atherosclerosis as measured by computed tomography-detectable coronary artery calcium (CAC)...
  7. ncbi Improvements in glycemic control in type 2 diabetes patients switched from sulfonylurea coadministered with metformin to glyburide-metformin tablets
    William Duckworth
    Carl T. Hayden VA Medical Center, Phoenix, AZ, USA
    J Manag Care Pharm 9:256-62. 2003
    ..A randomized, prospective trial comparing these 2 methods of treatment is needed, however, to determine the precise effect provided by the unique formulation of glyburide in the glyburide-metformin tablet...
  8. ncbi Preliminary report: hepatic fat and inflammation in type 2 diabetes mellitus
    Aramesh Saremi
    Phoenix VA Health Care System, Phoenix, AZ 85012 1892, USA
    Metabolism 59:430-2. 2010
    ..These data support the concept that accumulation of hepatic fat is related to enhanced inflammation in type 2 diabetes mellitus independent of general measures of obesity and standard cardiovascular risk factors...
  9. ncbi Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D)
    Linda F Fried
    Veterans Affairs Pittsburgh Healthcare System and Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylviania 15240, USA
    Clin J Am Soc Nephrol 4:361-8. 2009
    ..This paper discusses the design and key methodological issues that arose during the planning of the study...
  10. ncbi Blood pressure and cardiovascular disease risk in the Veterans Affairs Diabetes Trial
    Robert J Anderson
    Section of Endocrinology, VA Medical Center, Omaha, Nebraska, USA
    Diabetes Care 34:34-8. 2011
    ..Our objective was to determine whether baseline and follow-up (On-Study) systolic blood pressure (SBP), diastolic blood pressure (DBP), and SBP combined with DBP predict CVD events in the Veterans Affairs Diabetes Trial (VADT)...
  11. ncbi Design of the cooperative study on glycemic control and complications in diabetes mellitus type 2: Veterans Affairs Diabetes Trial
    Carlos Abraira
    VA Medical Center, Miami, FL 33125, USA
    J Diabetes Complications 17:314-22. 2003
    ..Recruitment is proceeding on schedule: the current mean HbA1c at entry is 9.4+/-1.6% and mean duration of diagnosed diabetes 11+/-8 years...
  12. ncbi The association between metabolic control and prevalent macrovascular disease in Type 2 diabetes: the VA Cooperative Study in diabetes
    M Sue Kirkman
    The Roudebush Veterans Affairs Medical Center, Indianapolis, IN, USA
    J Diabetes Complications 20:75-80. 2006
    ....
  13. ncbi Ethnicity, race, and baseline retinopathy correlates in the veterans affairs diabetes trial
    Nicholas Emanuele
    Research Service, Hines Veterans Affairs Hospital, Hines, Illinois, USA
    Diabetes Care 28:1954-8. 2005
    ....